New resource highlights costs and benefits of falls prevention interventions

New resource highlights costs and benefits of falls prevention interventions

February 19 2018 A new return on investment tool has been published bringing together evidence on...

FSRH issues statement contraception for women using known teratogenic drugs

FSRH issues statement contraception for women using known teratogenic drugs

February 16 2018 New guidance has been issued advising about contraceptive options for women...

PHE seeks feedback on usefulness of Smokefree Health Harms resources

PHE seeks feedback on usefulness of Smokefree Health Harms resources

February 15 2018 Public Health England is asking for health professionals to give feedback on...

Long-term opioid prescribing is increasing, finds BJGP study

Long-term opioid prescribing is increasing, finds BJGP study

February 14 2018 GPs have increased long-term opioid prescribing for non-cancer pain against...

'Stay Well Pharmacy' promotes community pharmacy to parents for children's minor ailments

'Stay Well Pharmacy' promotes community pharmacy to parents for children's minor ailments

February 12 2018 A new campaign is urging parents to consult a pharmacist first if their child...

  • New resource highlights costs and benefits of falls prevention interventions

    New resource highlights costs and benefits of falls prevention interventions

    Monday, 19 February 2018 11:06
  • FSRH issues statement contraception for women using known teratogenic drugs

    FSRH issues statement contraception for women using known teratogenic drugs

    Friday, 16 February 2018 18:12
  • PHE seeks feedback on usefulness of Smokefree Health Harms resources

    PHE seeks feedback on usefulness of Smokefree Health Harms resources

    Thursday, 15 February 2018 16:13
  • Long-term opioid prescribing is increasing, finds BJGP study

    Long-term opioid prescribing is increasing, finds BJGP study

    Wednesday, 14 February 2018 14:48
  • 'Stay Well Pharmacy' promotes community pharmacy to parents for children's minor ailments

    'Stay Well Pharmacy' promotes community pharmacy to parents for children's minor ailments

    Monday, 12 February 2018 14:37

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Professional News

February 21 2018 Public Health Wales has published further information about the tendering process for GP software which has seen EMIS Health not able to continue as a supplier.
February 20 2018 New British Thoracic Society guidelines on pleural mesothelioma include some key recommendations for primary care. The BTS guideline give recommendations and good practice points...